



32-1502

Customer Number: 000959

**DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM  
UNDER RULE 1.53(b) (former Rule 1.60)**

DOCKET NUMBER	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:		PRIOR APPLICATION SERIAL NUMBER: 09/261,599	PRIOR APPLICATION FILING DATE: FEBRUARY 26, 1999
MNI-204CP2DV1	CLASS:	SUBCLASS:	EXAMINER: BRANNOCK	ART UNIT: 1646

COMMISSIONER FOR PATENTS  
BOX PATENT APPLICATION  
WASHINGTON, DC 20231

A  
10/077698  
02/13/02

**CERTIFICATION UNDER 37 CFR 1.10**

Date of Deposit: February 13, 2002 Mailing Label Number: EL 892 199 437 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Assistant Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Larry Taylor

Name of Person Mailing Paper

  
Signature of Person Mailing Paper

Dear Sir:

This is a request for filing a  continuation  divisional application under 37 CFR 1.53(b), of pending prior application serial no. 09/261,599 filed on February 26, 1999, of M. Alexandra Glucksmann and Fong-Ying Tsai entitled 14273 Receptor, A Novel G-Protein Coupled Receptor.

1.  Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed. The copy of the enclosed papers is as follows:
  - 73 page(s) of specification
  - 5 page(s) of claims
  - 1 page(s) of abstract
  - 14 sheet(s) of drawing
  - \_\_\_\_\_ page(s) of declaration and power of attorney.

I hereby verify that the attached papers are a true copy of the prior complete application serial no. 09/261,599 as originally filed on February 26, 1999.

2.  Also enclosed are 10 Sheets of Sequence Listing
3.  The filing fee is calculated below:

	NUMBER OF CLAIMS FILED			NUMBER EXTRA
TOTAL	* 147	MINUS	** 20	= 127
INDEP	* 21	MINUS	*** 3	= 18
<input checked="" type="checkbox"/> MULTIPLE DEPENDENT CLAIMS				

SMALL ENTITY	
RATE	FEES
x 9 =	\$0.00
x 42 =	\$0.00
+140 =	\$0.00
BASIC FEE	\$0.00
TOTAL	\$0.00

OTHER THAN A SMALL ENTITY	
RATE	FEES
x 18 =	\$2286.00
x 84 =	\$1512.00
+ 280 =	\$280.00
BASIC FEE	\$740.00
TOTAL	\$4818.00


4.  The Commissioner is hereby authorized to charge any additional fees which may be required in connection with this communication, or credit any overpayment, to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.
5.  A check in the amount of \$4818.00 is enclosed for payment of the filing fee.

6.  A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claims in the prior application.)
7.  Amend the specification by replacing lines 3-9 at page 1 with the following: "This application is a divisional application of application no. 09/261,599 filed on February 26, 1999, Pending, which in turn is a continuation-in part of copending U.S. Patent Application Serial No. 09/223,538, filed December 30, 1998, and entitled "14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR", which is a continuation-in-part of copending U.S. Patent Application Serial No. 09/107,761, filed June 30, 1998, and entitled "14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR". The contents of all of the aforementioned application(s) are hereby incorporated by reference."
8.  The prior application is assigned of record to Millennium Pharmaceuticals, Inc.. A copy of the assignment in the prior application is enclosed.
9.  Also enclosed is a Statement of Limited Recognition Under 37 C.F.R. §10.9(b).
10.  The power of attorney in the prior application is to Lahive & Cockfield LLP.
  - a.  The power appears in the original papers in the prior application.
  - b.  Since the executed power does not appear in the original papers, a copy of the executed power and a copy of the executed Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney from the prior application is enclosed.
  - c.  A new power has been executed and is attached.
11.  Address all future communications (May only be completed by applicant, or attorney or agent of record) to Amy E. Mandragouras at **Customer Number: 000959** whose address is:

Lahive & Cockfield, LLP  
28 State Street  
Boston, Massachusetts 02109

12.  Any requests for extensions of time necessary in the parent application for establishing copendency between this application and the parent application are hereby requested and the Commissioner is authorized to charge any fee associated with such an extension to Deposit Account No. 12-0080.
13.  Pursuant to 37 CFR 1.821(e), the computer readable form of the sequence listing for this new application is to be identical with the computer readable form of application serial no. 09/261,599. Please use the computer readable form of application serial no. 09/261,599 in lieu of filing a duplicate computer readable form in this application. Pursuant to 37 CFR 1.821(f), the content of the paper copy of the sequence listing for this new application and the computer readable form of application serial no. 09/261,599 are the same.

February 13, 2002  
Date

  
Maria C. Laccotripe, Ph.D.  
Attorney for Applicants  
Limited Recognition Under 37 C.F.R. §10.9(b)

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, Massachusetts 02109  
Tel. (617) 227-7400